192 related articles for article (PubMed ID: 34681717)
1. NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models.
Gruijs M; Ganzevles SH; Stigter-van Walsum M; van der Mast R; van Ostaijen-Ten Dam MM; Tuk CW; Schilham MW; Leemans CR; Brakenhoff RH; van Egmond M; van de Ven R; Bakema JE
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681717
[TBL] [Abstract][Full Text] [Related]
2. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
[TBL] [Abstract][Full Text] [Related]
6. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
Front Immunol; 2021; 12():737311. PubMed ID: 34557197
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Specific Antibody, Cetuximab, Enhances the
Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
Front Immunol; 2020; 11():591139. PubMed ID: 33281820
[TBL] [Abstract][Full Text] [Related]
8. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Mediates Dysfunction in Activated PD-1
Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
[TBL] [Abstract][Full Text] [Related]
10. Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.
Dietsch GN; Lu H; Yang Y; Morishima C; Chow LQ; Disis ML; Hershberg RM
PLoS One; 2016; 11(2):e0148764. PubMed ID: 26928328
[TBL] [Abstract][Full Text] [Related]
11. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
López-Albaitero A; Lee SC; Morgan S; Grandis JR; Gooding WE; Ferrone S; Ferris RL
Cancer Immunol Immunother; 2009 Nov; 58(11):1853-64. PubMed ID: 19319529
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
[TBL] [Abstract][Full Text] [Related]
13. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent.
Cheng Y; Borcherding N; Ogunsakin A; Lemke-Miltner CD; Gibson-Corley KN; Rajan A; Choi AB; Wongpattaraworakul W; Chan CHF; Salem AK; Weiner GJ; Simons AL
Sci Rep; 2021 Jan; 11(1):1535. PubMed ID: 33452311
[TBL] [Abstract][Full Text] [Related]
15. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
16. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
17. Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway.
Long S; Gu Y; An Y; Lin X; Chen X; Wang X; Liao C; Ouyang W; Wang N; He Z; Zhao X
J Transl Med; 2021 May; 19(1):185. PubMed ID: 33933132
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD137 enhances the efficacy of cetuximab.
Kohrt HE; Colevas AD; Houot R; Weiskopf K; Goldstein MJ; Lund P; Mueller A; Sagiv-Barfi I; Marabelle A; Lira R; Troutner E; Richards L; Rajapaska A; Hebb J; Chester C; Waller E; Ostashko A; Weng WK; Chen L; Czerwinski D; Fu YX; Sunwoo J; Levy R
J Clin Invest; 2014 Jun; 124(6):2668-82. PubMed ID: 24837434
[TBL] [Abstract][Full Text] [Related]
19. Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
Friedman J; Padget M; Lee J; Schlom J; Hodge J; Allen C
Oral Oncol; 2019 Mar; 90():38-44. PubMed ID: 30846174
[TBL] [Abstract][Full Text] [Related]
20. Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer.
Jacobs MT; Wong P; Zhou AY; Becker-Hapak M; Marin ND; Marsala L; Foster M; Foltz JA; Cubitt CC; Tran J; Russler-Germain DA; Neal C; Kersting-Schadek S; Chang L; Schappe T; Pence P; McClain E; Zevallos JP; Rich JT; Paniello RC; Jackson RS; Pipkorn P; Adkins DR; DeSelm CJ; Berrien-Elliott MM; Puram SV; Fehniger TA
Clin Cancer Res; 2023 Oct; 29(20):4196-4208. PubMed ID: 37556118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]